Pantoprazole
- Generic Name
- Pantoprazole
- Brand Names
- Protonix, Somac Control, Tecta, Pantozol Control, Controloc Control
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F2N3O4S
- CAS Number
- 102625-70-7
- Unique Ingredient Identifier
- D8TST4O562
- Background
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...
- Indication
Pantoprazole Injection:
Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis
...
- Associated Conditions
- Erosive Esophagitis, GERD With Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Zollinger-Ellison Syndrome, Conditions where a reduction of gastric acid secretion is required, Pathological hypersecretory conditions
- Associated Therapies
- -
Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT02533349
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Stress Ulcer Prophylaxis in the Intensive Care Unit
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Dr. Morten Hylander Møller
- Target Recruit Count
- 3350
- Registration Number
- NCT02467621
- Locations
- 🇩🇰
Dept. of Intensive Care, Århus University Hospital Skejby, Arhus, Denmark
🇨🇭Dept. of Intensive Care, Basel University Hospital, Basel, Switzerland
🇬🇧Dept. of Intensive Care, University Hospital of Wales, Cardiff, United Kingdom
Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Chung-Tai Wu
- Target Recruit Count
- 114
- Registration Number
- NCT02466919
Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 153
- Registration Number
- NCT02432456
- Locations
- 🇺🇸
Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Dr. Waheed Rehman
- Target Recruit Count
- 14
- Registration Number
- NCT02345239
Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 91
- Registration Number
- NCT02290327
- Locations
- 🇨🇦
Queen Elizabeth II, Halifax, Nova Scotia, Canada
🇦🇺Royal Adelaide, Adelaide, Australia
🇨🇦St. Joseph's HealthCare Hospital, Hamilton, Ontario, Canada
Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02264106
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 3
- Registration Number
- NCT02235311
- Locations
- 🇺🇸
University Hospital, Columbia, Missouri, United States
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- University of British Columbia
- Registration Number
- NCT02213887
- Locations
- 🇨🇦
UBC Hospital - Detwiller Pavilion, Vancouver, British Columbia, Canada
A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 70
- Registration Number
- NCT02214433
- Locations
- 🇺🇸
Early Phase Clinical Unit, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.